UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $186.74 Million Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 8.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,767,901 shares of the medical equipment provider’s stock after purchasing an additional 140,531 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Zimmer Biomet were worth $186,743,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of ZBH. Franklin Resources Inc. increased its holdings in shares of Zimmer Biomet by 398.7% in the fourth quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider’s stock valued at $369,469,000 after purchasing an additional 2,796,372 shares in the last quarter. Norges Bank acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $216,223,000. Dodge & Cox increased its holdings in shares of Zimmer Biomet by 12.0% in the fourth quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider’s stock valued at $2,019,480,000 after purchasing an additional 2,044,645 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in shares of Zimmer Biomet by 191.8% in the fourth quarter. Nuveen Asset Management LLC now owns 1,389,405 shares of the medical equipment provider’s stock valued at $146,763,000 after purchasing an additional 913,310 shares in the last quarter. Finally, Sound Shore Management Inc. CT acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $81,447,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on ZBH. Raymond James reduced their price objective on shares of Zimmer Biomet from $119.00 to $104.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 6th. JMP Securities reduced their price objective on shares of Zimmer Biomet from $140.00 to $125.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 7th. Barclays reduced their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Monday, February 10th. Canaccord Genuity Group reduced their price objective on shares of Zimmer Biomet from $115.00 to $101.00 and set a “hold” rating on the stock in a research note on Monday, May 12th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Zimmer Biomet in a research note on Monday, April 14th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and an average target price of $111.53.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the business’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. The trade was a 14.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.39% of the company’s stock.

Zimmer Biomet Trading Down 1.2%

ZBH opened at $91.65 on Friday. The stock has a market capitalization of $18.13 billion, a P/E ratio of 20.60, a P/E/G ratio of 1.95 and a beta of 0.78. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.92 and a 12 month high of $119.06. The firm’s fifty day simple moving average is $102.24 and its 200 day simple moving average is $105.48. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $1.91 billion for the quarter, compared to analysts’ expectations of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The firm’s revenue was up 1.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.94 EPS. As a group, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were paid a $0.24 dividend. The ex-dividend date of this dividend was Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 1.05%. Zimmer Biomet’s payout ratio is currently 21.24%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.